The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Active:	No
Cancer Type:	Cancer-Related Syndrome Leukemia Myelodysplastic Syndromes (MDS)	NCT ID:	NCT01566695
Trial Phases:	Phase III	Protocol IDs:	AZA-MDS-003 (primary) 2012-002471-34
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Celgene
NCI Full Details:	http://clinicaltrials.gov/show/NCT01566695

Summary

Evaluation of the Efficacy and Safety of Oral Azacitidine plus Best Supportive care
versus Placebo and Best Supportive care in subjects with red blood cell (RBC)
transfusion-dependent anemia and thrombocytopenia due to International Prognostic Scoring
System (IPSS) lower risk myelodysplastic syndromes (MDS).

Treatment Sites in Georgia

Phoebe Cancer Center at Phoebe Putney Memorial Hospital
425 Third Avenue
Albany, GA 31702
229-312-5091
www.phoebehealth.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.